



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Letter to the Editor

Response to “Comments on whole lung irradiation as a novel treatment for COVID-19: Final results of the prospective randomized trial (WINCOVID trial)”



To the Editor

We went through the comments put forward by Özyürek et al. [1] and firstly, we thank the authors and appreciate their interest in our manuscript [2]. First, regarding COVID-19 vaccination, most of the patient accrual happened around the time of initial phase of vaccine rollout in the country. Our Institutional scientific review committee advised against inclusion of vaccinated individuals in the clinical trial as there might be a confounding effect while reporting unforeseen adverse effects due to either the vaccine or LDRT. Therefore, none of the participants were vaccinated (partially/whole) at the time of their inclusion in the study.

Second, regarding the smoking status, Eight out of 34 participants in the LDRT arm were smokers. Two patients (75/Male, 25 pack years and 43/Male, 20 pack years) had died amongst these eight. In the control arm, five out of 17 participants were smokers. Two out of these five had died (54/Male, 18 pack years and 60/Male, 14 pack years).

Third, about the inflammatory markers response, we would like to clarify that the LDRT group, in fact had significant reduction in inflammatory biomarkers- CRP, IL-6 and Serum ferritin on comparison of their day 7 and day 14 values with the baseline. We had observed similar reduction in control group as well. Therefore, the ‘within-group’ comparisons were statistically significant. The manuscript presented a ‘between-group’ comparison that did not achieve statistical significance. Systemic inflammatory markers may be subject to variations in presence of co-existing bacterial infections as mentioned in the manuscript. The anti-inflammatory effect has translated to rapid and evident clinical improvement backed by discernible radiological resolution implying the additional therapeutic benefit with LDRT compared to pharmacological therapy alone.

Lastly, we agree that the notable difference in comorbidities between the patient groups was one of the drawbacks of the study. Age, sex and comorbidities based stratified analysis would have allowed for better interpretation of the study results. But, this would have meant longer time to recruit patients. In the face of ongoing pandemic and acute oxygen crisis in our country at that

time, we felt it was better for the study results to be published as soon as possible [3].

We once again thank Özyürek et al. for raising valid and relevant scientific queries and comments on our manuscript.

References

- [1] Özyürek Y, Sari SY, Hurmuz P. Comments on “Whole lung irradiation as a novel treatment for COVID-19: Final results of the prospective randomized trial (WINCOVID trial)”. *Radiother Oncol* 2022.
- [2] Ganesan G, Ponniah S, Sundaram V, Marimuthu PK, Pitchaikannu V, Chandrasekaran M, et al. Whole lung irradiation as a novel treatment for COVID-19: final results of the prospective randomized trial (WINCOVID trial). *Radiother Oncol* 2022;167:133–42.
- [3] Ganesan G, Ponniah S, Sundaram V, Marimuthu PK, Pitchaikannu V, Chandrasekaran M, et al. Whole lung irradiation as a novel treatment for COVID-19: interim results of an ongoing phase 2 trial in India. *Radiother Oncol* 2021;1:83–90.

Govindaraj Ganesan ^{a,*}

Sasipriya Ponniah ^a

Vivek Sundaram ^b

Praveen Kumar Marimuthu ^a

Venkatraman Pitchaikannu ^a

Manikandan Chandrasekaran ^a

Janakiraman Thangarasu ^c

Gunasekaran Kannupaiyan ^a

Prabhu Ramamoorthy ^a

Brindha Thangaraj ^a

Harshavardhanan Sasipriya Govindaraj ^a

Shree Vaishnavi Raguram ^a

^a Harshamitra Super-Specialty Cancer Centre and Research Institute, Trichy, India

^b Sundaram Hospital, Trichy, India

^c RPS Hospitals, Chennai, India

* Corresponding author at: No.41, Nachiyar Kovil Road, Harshamitra Super Specialty Cancer Centre and Research, Institute, Woraiyur, Trichy 620003, Tamilnadu, India.

E-mail address: govindarajganesan@gmail.com (G. Ganesan)

Received 23 February 2022

Accepted 28 February 2022

Available online 10 March 2022

* DOI of original article: <https://doi.org/10.1016/j.radonc.2022.02.035>

<https://doi.org/10.1016/j.radonc.2022.02.037>

0167-8140/© 2022 Elsevier B.V. All rights reserved.